<DOC>
	<DOCNO>NCT01421212</DOCNO>
	<brief_summary>The purpose study find best monthly dose schedule new Hepatitis Immune Globulin ( Boca HBVIg , study drug ) use combination antiviral agent Lamivudine liver transplantation . Boca HBVIg give along Lamivudine prevent hepatitis B reinfection follow liver transplantation patient end stage liver failure due hepatitis B infection .</brief_summary>
	<brief_title>Pilot Study Assess Pharmacokinetics Intravenous Nabi 5 % Hepatitis B Immune Globulin ( Boca HBVIg ) Used Combination With Lamivudine Patients With Hepatitis B Virus ( HBV ) Associated Liver Disease Undergoing Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Be 18 year old great , either male female , ethnic background . Be positive HBsAg . Patients may either positive negative antiHDV , HBeAg , HBV DNA ( nonPCR assay ) . Be diagnose HBVinduced liver disease include either : HBsAg positive cirrhosis , HBsAg positive presence hepatocellular carcinoma ( HCC ) evidence vascular invasion extrahepatic spread , either : single tumor large 5 cm diameter , three tumor , large great 3 cm diameter . Have receive least one dose Lamivudine 100 mg po qd prior transplantation . Fulfill UNOS minimal listing criterion . Have receive approval liver transplantation respective participate center list Status 2 3 felt within three month liver transplantation . If require retransplantation primary graft nonfunction hepatic artery thrombosis , retransplantation must take place within first four week initial transplant evidence recurrent hepatitis B . Be able willing give write informed consent . In patient Grade 3 4 hepatic encephalopathy , legal guardian must available provide consent . In case minor , parent guardian must provide consent . If woman childbearing potential , negative serum beta HCG pregnancy test within 14 day prior start Lamivudine therapy within 14 day prior transplant agree practice contraception study ( total 36 week ) . Eligible patient must : Require retransplantation recurrent hepatitis B . Have chronic hepatitis B liver disease history breakthrough infection Lamivudine Have cause liver disease include chronic hepatitis C. Have HCC meet Inclusion Criterion # 3 , require systemic chemotherapy . Be seropositive HIV infection . Be use experimental device receive experimental drug . Be participate clinical treatment trial investigational drug within 30 day prior liver transplantation plan receive another investigational drug study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2011</verification_date>
	<keyword>Liver Transplantation</keyword>
	<keyword>Liver Disease</keyword>
	<keyword>Hepatitis B</keyword>
	<keyword>Hepatitis B Infection</keyword>
	<keyword>Hepatitis B Associated Liver Disease</keyword>
	<keyword>HBV</keyword>
</DOC>